Clinical trials: Skin Infection
Hidradenitis Suppurativa
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa.
- Trial name
- NCT05635838
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 20 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Osteoarthritis, Rheumatoid Arthritis
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Back Pain, Acute Upper Respiratory Tract Infection
- Trial name
- NCT05214690
- Testing
- DW1809-T2, DW1809-1
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Tinea Pedis
A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b study in adult participants with tinea pedis caused by dermatophytes.
- Trial name
- NCT07668999
- Testing
- ZYG24004 1% topical film-forming formulation, ZYG24004 3% topical film-forming formulation
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sinomune Pharmaceutical Co., Ltd
Hidradenitis Suppurativa
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.
- Trial name
- HB0043-HS-0-01 (NCT06895499)
- Testing
- HB0043
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Hidradenitis Suppurativa (HS)
A Study With CIT-013 in HS Patients
The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013.
- Trial name
- Citylights (NCT06993233)
- Testing
- CIT-013 high dose, CIT-013 medium dose
- Where
- 28 sites in Canada, Germany and 4 more
- Volunteers
- 108 people
- Sponsor
- Citryll BV
Onychomycosis
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis
This is a randomized, observer-blinded, Aqueous Gel-controlled trial examining the safety and efficacy of daily application of DBI-001 Gel vs. DBI-002 Gel vs. Aqueous Gel for 24 consecutive weeks in subjects with onychomycosis.
- Trial name
- NCT05491603
- Testing
- DBI-001, DBI-002, Aqueous Gel
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- DermBiont, Inc.
Herpes Labialis, HSV
A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis
Primary Objective: To assess local and generalized adverse events with repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12…
- Trial name
- NCT03521479
- Testing
- Squaric Acid Dibutyl Ester
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Squarex, LLC
Tinea Pedis
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis
A prospective, open post-market clinical investigation that will enroll male and female subjects diagnosed with foot fungus and at least one of the following conditions: heal cracks, calluses and/or dry feet.
- Trial name
- NCT03676686
- Testing
- Nåva Foot Cream
- Where
- 3 sites in Sweden
- Volunteers
- 46 people
- Sponsor
- Natumin Pharma AB
Hidradenitis Suppurativa (HS)
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
- Trial name
- NCT07213973
- Testing
- Povorcitinib
- Where
- 30 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Surgical Site Infection
Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™
The purpose of this pilot study is to evaluate antimicrobial properties of a single test product, a vehicle product and a reference product applied in two different areas when used as a patient preoperative skin preparation.
- Trial name
- ZX-ZP-0035 (NCT02221232)
- Testing
- Chloraprep, ZuraPrep, ZuraPrep Vehicle
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Zurex Pharma, Inc.
Cold Sore
A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers
Comparison of the efficacy of penciclovir 10 mg/g (1%) cream with that of vehicle at 72 hours in preventing the appearance of classical lesions following prodromal symptoms (tingling or burning sensation) based on thermographic…
- Trial name
- NCT00820534
- Testing
- Penciclovir
- Where
- United Kingdom
- Volunteers
- 126 people
- Sponsor
- Novartis
Impetigo
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.
- Trial name
- NCT02090764
- Testing
- Ozenoxacin
- Where
- Puerto Rico
- Volunteers
- 412 people
- Sponsor
- Ferrer Internacional S.A.
Prophylaxis for Herpes Simplex
Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects
This study will evaluate, versus a placebo, the safety of Herpes simplex candidate vaccine with adjuvant in initially HSV seropositive or seronegative subjects who have no genital herpes disease.
- Trial name
- NCT00698568
- Testing
- Herpes simplex candidate vaccine- adjuvanted GSK 208141
- Where
- 47 sites in United States, Australia and 10 more
- Volunteers
- 7,460 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Infections, Herpesviridae
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
- Trial name
- NCT00116844
- Testing
- Valaciclovir
- Where
- 17 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Drug-Drug Interaction Study: ASP2151 and Midazolam
CYP3A4 is involved in the metabolism of many drugs. So, it is important to assess in vivo the induction effect of ASP2151 on that enzyme to determine the extent of any possible drug interactions.
- Trial name
- NCT02403635
- Testing
- Midazolam, ASP2151
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
Hidradenitis Suppurativa
Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting
This study will assess the effects of adalimumab treatment in moderate to severe Hidradenitis Suppurativa (HS) patients in the real world setting.
- Trial name
- HARMONY (NCT02786576)
- Where
- 83 sites in Austria, Belgium and 11 more
- Volunteers
- 236 people
- Sponsor
- AbbVie
Melanoma, Herpetic Infection
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients…
- Trial name
- NCT02910557
- Where
- 23 sites in United States, Austria and 3 more
- Volunteers
- 187 people
- Sponsor
- Amgen
Bacterial Infections
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
This study is aimed to evaluate the efficacy and safety between Tedizolid 200mg daily (intra venous) I.V. to oral for 6-day treatment compared with that of Linezolid 600mg twice daily I.V.
- Trial name
- NCT02066402
- Testing
- Tedizolid (BAY119-2631), Linezolid
- Where
- 55 sites in United States, China and 2 more
- Volunteers
- 598 people
- Sponsor
- Bayer
Sarcoma, Kaposi, HIV Infections
Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma and lymphoproliferative disorders.
- Conditions
- Sarcoma, Kaposi, HIV Infections, Lymphoproliferative Disorders
- Trial name
- NCT00002153
- Testing
- A-007
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- DEKK-TEC, Inc.